AnalystBook Research · Company Intelligence

RCM TECHNOLOGIES, INC.

RCMTNasdaq

Built from RCM TECHNOLOGIES, INC.'s own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

RCM Technologies converted double-digit growth into higher profit and free cash flow, but newly disclosed material weaknesses qualify an otherwise strong operating year.

The read at a glance✓ Audited against SEC data
  • GrowthRevenue grew 14.7%OK
  • ProfitabilityNet income grew 22.6% to $16.334M from $13.327MOK
  • Cash flowFree cash flow grew 382.8% to $17.37M from $3.598MOK
  • MarginsOperating margin contracted 16 bps to 7.86%Watch
  • AccountingBroad operating improvement; controls ineffectiveNote
  • Insiders0 purchases and 28 salesWatch

Business

RCM Technologies provides specialty healthcare staffing, engineering services and life-sciences and information-technology solutions.

Where the revenue comes from

Fiscal 2025, as RCM TECHNOLOGIES, INC. reports it. History and quarterly detail are in the app.

  • Specialty Health Care$164.1M
  • Engineering$120.5M
  • Life Sciences, Data & Solutions$34.8M

Latest filings

  • 8-K · Company announcement2026-08-31
  • 10-Q · Quarterly report2026-08-13
  • 10-Q · Quarterly report2026-05-14
  • 8-K · Company announcement2026-05-04
  • 8-K · Company announcement2026-04-03
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about RCM TECHNOLOGIES, INC., every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.